News & Events

Philogen announces the completion of a second interim analysis of its phase III clinical program with NidlegyTM for the treatment of melanoma

Jan 13, 2021

NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated.
Data Safety Monitoring Board recommends to continue the study as planned.

PRESS RELEASE – 13/01/2021